Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Cash from Operations (2017 - 2025)

Aclaris Therapeutics has reported Cash from Operations over the past 9 years, most recently at 13131000.0 for Q4 2025.

  • Quarterly results put Cash from Operations at 13131000.0 for Q4 2025, down 46.91% from a year ago — trailing twelve months through Dec 2025 was 47113000.0 (down 134.68% YoY), and the annual figure for FY2025 was 47113000.0, down 134.68%.
  • Cash from Operations for Q4 2025 was 13131000.0 at Aclaris Therapeutics, down from 10932000.0 in the prior quarter.
  • Over the last five years, Cash from Operations for ACRS hit a ceiling of 22000000.0 in Q3 2024 and a floor of 26353000.0 in Q1 2023.
  • Median Cash from Operations over the past 5 years was 12689500.0 (2024), compared with a mean of 13260700.0.
  • Biggest five-year swings in Cash from Operations: plummeted 214.15% in 2023 and later soared 189.59% in 2024.
  • Aclaris Therapeutics' Cash from Operations stood at 17075000.0 in 2021, then decreased by 11.95% to 19115000.0 in 2022, then soared by 64.63% to 6761000.0 in 2023, then tumbled by 32.2% to 8938000.0 in 2024, then plummeted by 46.91% to 13131000.0 in 2025.
  • The last three reported values for Cash from Operations were 13131000.0 (Q4 2025), 10932000.0 (Q3 2025), and 9993000.0 (Q2 2025) per Business Quant data.